Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-RAD LABORATORIES, INC.BIO BIO.B · Entity 2247 | Director | April 21, 2026 | April 23, 2026 |
| CORELOGIC, INC.CLGX · Entity 138562 | CLO & Corporate Secretary | March 04, 2019 | March 06, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-RAD LABORATORIES, INC.
Report date April 21, 2026 · Filed April 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Bio-Rad A Common StockSEC Table I · non-derivative | Direct | 715 |
Reported balance
After 2026-04-21 transaction · row 1
1 source rowRow 1 · 2026-04-21 · Exercise / conversion · Acquired 407 · Balance 715 F1: Shares of Class A common stock acquired on the vesting of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 369 |
Reported balance
After 2026-04-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-21 · Grant · Acquired 369 · Balance 369 F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-04-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-21 · Exercise / conversion · Disposed 407 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Class A common stock acquired on the vesting of restricted stock units.
F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
F3: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders.
CORELOGIC, INC.
Report date March 04, 2019 · Filed March 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,161 |
Reported balance
After 2019-03-04 transaction · row 1
1 source rowRow 1 · 2019-03-04 · Grant · Acquired 4,033 · Balance 24,161 F1: Amount represents performance-based restricted stock units ("PBRSUs") granted in 2018 that were credited upon Compensation Committee certification of Issuer's achievement of 2018 performance metric on March 4, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Amount represents performance-based restricted stock units ("PBRSUs") granted in 2018 that were credited upon Compensation Committee certification of Issuer's achievement of 2018 performance metric on March 4, 2019.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
JANUS CAPITAL GROUP INC
Report date May 30, 2017 · Filed June 01, 2017
Section 16 reporting ended · disclosed 2017-06-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-05-30 transaction · row 1
1 source rowRow 1 · 2017-05-30 · Disposition to issuer · Disposed 8,717 · Balance 0 F1: On May 30, 2017, pursuant to that certain Agreement and Plan of Merger, dated as of October 3, 2016 (the "Merger Agreement"), by and among Henderson Group plc ("Henderson"), a company incorporated in Jersey, Horizon Orbit Corp., a Delaware corporation and direct wholly-owned subsidiary of Henderson ("Merger Sub"), and Janus Capital Group Inc., a Delaware corporation ("JCG"), JCG and Henderson (which has been renamed as Janus Henderson Group plc ("Janus Henderson")) completed the merger-of-equals whereby the Merger Sub merged with and into JCG, with JCG surviving the merger as a direct wholly-owned subsidiary of Janus Henderson (the "Merger"). F2: Pursuant to the Merger Agreement, each share of JCG common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the completion of the Merger was automatically converted into the right to receive 0.47190 of a fully paid up Janus Henderson ordinary share, par value Pound 0.125 per share ("Ordinary Shares"), together with cash in lieu of any fractional Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 30, 2017, pursuant to that certain Agreement and Plan of Merger, dated as of October 3, 2016 (the "Merger Agreement"), by and among Henderson Group plc ("Henderson"), a company incorporated in Jersey, Horizon Orbit Corp., a Delaware corporation and direct wholly-owned subsidiary of Henderson ("Merger Sub"), and Janus Capital Group Inc., a Delaware corporation ("JCG"), JCG and Henderson (which has been renamed as Janus Henderson Group plc ("Janus Henderson")) completed the merger-of-equals whereby the Merger Sub merged with and into JCG, with JCG surviving the merger as a direct wholly-owned subsidiary of Janus Henderson (the "Merger").
F2: Pursuant to the Merger Agreement, each share of JCG common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the completion of the Merger was automatically converted into the right to receive 0.47190 of a fully paid up Janus Henderson ordinary share, par value Pound 0.125 per share ("Ordinary Shares"), together with cash in lieu of any fractional Ordinary Share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 21, 2026 Filed Apr 23, 2026 19:23 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 407 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001343989-26-000002 · wk-form4_1776972221.xml · derivative · entry 3 PINKSTON ARNOLD A · CIK 0001343989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 407 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. F3 · derivative.expiration_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 19:23 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | GrantRestricted Stock Units · Derivative | 369 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001343989-26-000002 · wk-form4_1776972221.xml · derivative · entry 2 PINKSTON ARNOLD A · CIK 0001343989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 369 Underlying: Bio-Rad A Common Stock · 369 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. F3 · derivative.expiration_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 19:23 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 407 | $0.00 | $0.00 |
DisclosureSEC source: 0001343989-26-000002 · wk-form4_1776972221.xml · nonDerivative · entry 1 PINKSTON ARNOLD A · CIK 0001343989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| April 22, 2025 Filed Apr 24, 2025 21:15 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 308 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-007908 · form4.xml · derivative · entry 3 PINKSTON ARNOLD A · CIK 0001343989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 308 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: On September 6, 2024, the reporting person was granted 308 restricted stock units, vesting at 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. F4 · derivative.expiration_date: On September 6, 2024, the reporting person was granted 308 restricted stock units, vesting at 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. Read SEC document |
| April 22, 2025 Filed Apr 24, 2025 21:15 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | GrantRestricted Stock Units · Derivative | 407 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-007908 · form4.xml · derivative · entry 2 PINKSTON ARNOLD A · CIK 0001343989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 407 Underlying: Bio-Rad A Common Stock · 407 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. F3 · derivative.expiration_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. Read SEC document |
| April 22, 2025 Filed Apr 24, 2025 21:15 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 308 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-007908 · form4.xml · nonDerivative · entry 1 PINKSTON ARNOLD A · CIK 0001343989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 17:54 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GrantRestricted Stock Units · Derivative | 308 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-016374 · form4.xml · derivative · entry 1 PINKSTON ARNOLD A · CIK 0001343989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308 Underlying: Bio-Rad A Common Stock · 308 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 20:30 UTC | CORELOGIC, INC. CLGX · Entity 138562 | GrantCommon Stock | 4,033 | $0.00 | $0.00 |
DisclosureSEC source: 0000036047-19-000040 · wf-form4_155192222373217.xml · nonDerivative · entry 1 PINKSTON ARNOLD A · CIK 0001343989 · CLO & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,161 F1 · shares: Amount represents performance-based restricted stock units ("PBRSUs") granted in 2018 that were credited upon Compensation Committee certification of Issuer's achievement of 2018 performance metric on March 4, 2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 20:52 UTC | CORELOGIC, INC. CLGX · Entity 138562 | Tax withholdingCommon Stock | 1,176 | $0.00 | $0.00 |
DisclosureSEC source: 0000036047-19-000030 · wf-form4_155183714457964.xml · nonDerivative · entry 2 PINKSTON ARNOLD A · CIK 0001343989 · CLO & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,128 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 20:52 UTC | CORELOGIC, INC. CLGX · Entity 138562 | GrantCommon Stock | 11,968 | $0.00 | $0.00 |
DisclosureSEC source: 0000036047-19-000030 · wf-form4_155183714457964.xml · nonDerivative · entry 1 PINKSTON ARNOLD A · CIK 0001343989 · CLO & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,304 F1 · shares: Represents time-vested stock units granted in 2019 that are subject to a performance metric for fiscal 2019. Read SEC document |
| March 05, 2018 Filed Mar 5, 2018 21:27 UTC | CORELOGIC, INC. CLGX · Entity 138562 | GrantCommon Stock | 9,336 | $0.00 | $0.00 |
DisclosureSEC source: 0000036047-18-000035 · wf-form4_152030321294638.xml · nonDerivative · entry 1 PINKSTON ARNOLD A · CIK 0001343989 · CLO & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,336 F1 · shares: Represents time-vested restricted stock units granted in 2018 that are subject to a performance metric for fiscal 2018. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 16:49 UTC | JANUS CAPITAL GROUP INC JNS · Entity 175616 | Disposition to issuerCommon Stock | 8,717 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-036941 · a4.xml · nonDerivative · entry 1 PINKSTON ARNOLD A · CIK 0001343989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: On May 30, 2017, pursuant to that certain Agreement and Plan of Merger, dated as of October 3, 2016 (the "Merger Agreement"), by and among Henderson Group plc ("Henderson"), a company incorporated in Jersey, Horizon Orbit Corp., a Delaware corporation and direct wholly-owned subsidiary of Henderson ("Merger Sub"), and Janus Capital Group Inc., a Delaware corporation ("JCG"), JCG and Henderson (which has been renamed as Janus Henderson Group plc ("Janus Henderson")) completed the merger-of-equals whereby the Merger Sub merged with and into JCG, with JCG surviving the merger as a direct wholly-owned subsidiary of Janus Henderson (the "Merger"). F2 · price: Pursuant to the Merger Agreement, each share of JCG common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the completion of the Merger was automatically converted into the right to receive 0.47190 of a fully paid up Janus Henderson ordinary share, par value Pound 0.125 per share ("Ordinary Shares"), together with cash in lieu of any fractional Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.